Beyond GLP-1: What Amylin Analogs Could Change About Weight Loss
CagriSema has an FDA application filed. Petrelintide has Phase 2 data. Here's what the amylin class actually is — and why it matters.
Now I have everything I need. Let me write the article.
Beyond GLP-1: What Amylin Analogs Could Change About Weight Loss
GLP-1 drugs rewired how we think about obesity treatment. But they work on one hormone pathway. Your body uses dozens. The next class of drugs coming through the pipeline targets a completely different signal — one your pancreas has been sending since the first time you ever ate a meal.
That signal is amylin. And the drugs being built around it might be about to change the game again.
What Amylin Actually Does
Amylin is a hormone released by the pancreas alongside insulin every time you eat. According to a foundational review published in Physiology & Behavior, amylinergic control of food intake works through the brainstem — slowing gastric emptying, suppressing glucagon, and sending satiety signals that tell you the meal is done. It's a separate circuit from GLP-1, which works more through the gut and hypothalamus.
People with obesity often have blunted amylin signaling. That's part of why the "I'm full" message doesn't land the way it should.
The idea behind amylin analogs is simple: if your own amylin signal is weak, give you a stronger, longer-acting version of it. The challenge has been doing that without the side effects that plagued pramlintide — the only FDA-approved amylin analog currently on the market, which requires multiple daily injections and causes significant nausea.
Cagrilintide: The One Everyone Is Watching
The most advanced amylin analog in development right now is cagrilintide (Novo Nordisk). It's a once-weekly injectable that acts on amylin and calcitonin receptors. A 2024 review in Cardiology Reviews specifically examined cagrilintide as a long-acting amylin analog for obesity treatment, laying out its mechanism and early clinical promise.
But the bigger story is what happens when you combine it with semaglutide.
The combination — called CagriSema — stacks an amylin analog on top of a GLP-1 receptor agonist, hitting two appetite pathways simultaneously. Two Phase 3 REDEFINE trials published in the New England Journal of Medicine in August 2025 reported results. REDEFINE 1 looked at adults with overweight or obesity without diabetes; REDEFINE 2 focused on adults with obesity and type 2 diabetes. Both trials involved coadministered cagrilintide and semaglutide, making them among the most significant obesity drug readouts published in years.
In December 2025, Novo Nordisk filed for FDA approval of CagriSema — described by PR Newswire as "the first once-weekly combination of GLP-1 and amylin analogues for weight management." A network meta-analysis published in Endocrinology, Diabetes & Metabolism in July 2026 compared CagriSema head-to-head with semaglutide, cagrilintide alone, and tirzepatide across randomized clinical trials — a sign that the research community is already stress-testing these combinations against the current standard of care.
Petrelintide: The Other Amylin in the Room
Cagrilintide isn't the only amylin analog in development. Petrelintide (Zealand Pharma, partnered with Roche) is a newer entry. Phase 1 safety and pharmacokinetics data were published in Diabetes, Obesity and Metabolism in July 2026, covering two randomized, controlled trials of petrelintide for weight management.
On the clinical trial side, a completed Phase 2 trial of once-weekly petrelintide versus placebo (NCT06662539) evaluated dose levels, body weight effects, safety, and tolerability in people with obesity or overweight with comorbidities. Roche reported over 10% weight loss for its Zealand-partnered amylin analogue, according to FirstWord PHARMA — a result that drew significant attention given how early-stage the program still is.
A 2026 review in Peptides also surveyed the broader landscape of long-acting amylin-related peptides as therapies for obesity and type 2 diabetes, suggesting petrelintide and similar molecules represent a meaningful new class — not just a footnote to GLP-1.
Why a Second Pathway Matters
The honest question is: if semaglutide and tirzepatide already work well, why does adding another pathway matter?
A few reasons. First, not everyone responds to GLP-1 agonists the same way — some people plateau earlier than others. Second, combining pathways may allow lower doses of each drug, which could reduce side effects. Third, the mechanisms are genuinely additive: GLP-1 slows gastric emptying and reduces appetite through the hypothalamus; amylin acts through the brainstem and also suppresses glucagon. They're not redundant.
A 2025 systematic review in Pharmacological Reviews on emerging pharmacotherapies for obesity specifically calls out amylin-based approaches as part of the next generation of treatment, alongside triple agonists and other combination strategies. A separate 2024 review in Expert Review of Clinical Pharmacology focused specifically on amylin analogs for obesity without diabetes — underscoring that the target population is broader than just people managing blood sugar.
There's also active research into what these drugs do beyond weight. An actively recruiting Phase 1 trial (NCT07010432) on ClinicalTrials.gov is investigating how cagrilintide affects bone metabolism in postmenopausal women with obesity — an important question, since bone density loss is a known concern with rapid weight loss.
What This Means for You
- Amylin analogs are real, not theoretical. CagriSema has an FDA application filed. Petrelintide has Phase 2 data. This isn't five years away — it's in review now.
- Combination approaches are the direction the field is heading. If you've plateaued on a GLP-1 drug, the next generation of options may work differently enough to matter.
- Ask your prescriber, not the headlines. Trial results are published in aggregate; your metabolic profile, history, and goals are individual. The research is promising — but it's a starting point for a conversation, not a prescription.
Not medical advice. Talk to your prescriber about your specific situation before making any changes to your treatment.
